1. Home
  2. INTS vs KTTA Comparison

INTS vs KTTA Comparison

Compare INTS & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$5.33

Market Cap

19.2M

Sector

Health Care

ML Signal

HOLD

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.69

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTS
KTTA
Founded
2012
2020
Country
United States
United States
Employees
N/A
4
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.2M
18.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
INTS
KTTA
Price
$5.33
$0.69
Analyst Decision
Buy
Strong Buy
Analyst Count
3
1
Target Price
$38.00
$3.00
AVG Volume (30 Days)
22.4K
630.8K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.28
52 Week High
$8.06
$2.06

Technical Indicators

Market Signals
Indicator
INTS
KTTA
Relative Strength Index (RSI) 43.31 40.31
Support Level $5.08 $0.68
Resistance Level $8.06 $0.78
Average True Range (ATR) 0.28 0.06
MACD -0.05 -0.00
Stochastic Oscillator 30.16 14.23

Price Performance

Historical Comparison
INTS
KTTA

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Share on Social Networks: